Related Experiment Video
Updated: Jan 14, 2026
Treating Low Back Pain in Failed Back Surgery Patients with Multicolumn-lead Spinal Cord Stimulation
Published on: June 26, 2018
Use of High-Frequency 10-kHz Spinal Cord Stimulation in the Treatment of Persistent Spinal Pain Syndrome Type 2: A
Saiganesh Ravikumar1, Brandon Stevens1, Te'Amrat Mehreteab2
1Department of Anesthesiology, Donald and Barbara Zucker School of Medicine At Hofstra/Northwell Health, Uniondale, NY, USA.
Objectives:
In 2015, 10-kHz high-frequency (10-kHz) spinal cord stimulation (SCS) received Food and Drug Administration approval to treat persistent spinal pain syndrome type 2 (PSPS-2). The outcomes of 10-kHz SCS on PSPS-2 have not been systematically reviewed. We systematically reviewed the relevant literature and hypothesized that 10-kHz SCS is safe and effective in managing pain in patients with PSPS-2.
Materials And Methods:
PUBMED and EMBASE data bases were searched with the query ((spinal cord stimulator) OR (spinal cord stimulation) OR (SCS)) AND (pain) AND ((10 khz) OR (10-khz) OR (HF10) OR (HF-10)) on April 24, 2024.
Results:
The search produced 636 nonduplicate articles. After applying the inclusion/exclusion criteria, nine studies were selected. Seven studies reported the percentage passing 10-kHz SCS trial, and the weighted average based on the number of patients was 87.3% success rate overall. Three studies measured overall pain on the visual analog scale (VAS), and six measured VAS back and leg separately. The weighted average for VAS overall, back, and leg was 8.1 (preoperation), 4.7 (postoperation); 7.0 (preoperation), 2.0 (postoperation); and 5.7 (preoperation), 1.6 (postoperation), respectively. Two studies evaluated the Beck Depression Index, and the weighted average was 23.8 (preoperation) and 14.0 (postoperation). Three studies evaluated the Oswestry Disability Index (ODI), and the weighted average was 48.3 (preoperation) and 30.6 (postoperation). Two studies compared burst stimulation with 10-kHz SCS, and both found no difference in back pain scores, whereas both studies found greater improvement in leg pain in the burst groups. Two studies compared low-frequency SCS with 10-kHz SCS, and both studies found no significant difference in VAS or ODI scores between the two treatments. There were no reported unanticipated adverse device effects across the studies.
Conclusion:
For many patients with refractory PSPS-2, 10-kHz SCS is a safe, effective treatment, but there is a lack of evidence of its superiority to burst or traditional SCS.
